Loading...

Brilliant Violet 605™ anti-mouse/human CD45R/B220 Antibody

Pricing & Availability
Clone
RA3-6B2 (See other available formats)
Regulatory Status
RUO
Other Names
B220
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RA3-6B2_BV605_052112
C57BL/6 mouse splenocytes were stained with CD45R/B220 (clone RA3-6B2) Brilliant Violet 605™ (filled histogram) or rat IgG2a, κ Brilliant Violet 605™ isotype control (open histogram).
  • RA3-6B2_BV605_052112
    C57BL/6 mouse splenocytes were stained with CD45R/B220 (clone RA3-6B2) Brilliant Violet 605™ (filled histogram) or rat IgG2a, κ Brilliant Violet 605™ isotype control (open histogram).
Compare all formats See Brilliant Violet 605™ spectral data
Cat # Size Price Quantity Check Availability Save
103243 125 µL 168€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103244 50 µg 210€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45R, also known as B220, is an isoform of CD45. It is a member of the protein tyrosine phosphatase (PTP) family with a molecular weight of approximately 180-240 kD. CD45R is expressed on B cells (at all developmental stages from pro-B cells through mature B cells), activated B cells, and subsets of T and NK cells. CD45R (B220) is also expressed on a subset of abnormal T cells involved in the pathogenesis of systemic autoimmunity in MRL-Faslpr and MRL-Fasgld mice. It plays a critical role in TCR and BCR signaling. The primary ligands for CD45 are galectin-1, CD2, CD3, and CD4. CD45R is commonly used as a pan-B cell marker; however, CD19 may be more appropriate for B cell specificity.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse, Human
Reported Reactivity
Cat
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Abelson murine leukemia virus-induced pre-B tumor cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone RA3-6B2 has been described to react with an epitope on the extracellular domain of the transmembrane CD45 glycoprotein which is dependent upon the expression of exon A and specific carbohydrate residues. Additional reported applications (for the relevant formats) include: immunoprecipitation1, in vitro and in vivo modulation of B cell responses2-4, immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections5,6, and spatial biology (IBEX)14,15.

Application References
  1. Coffman RL. 1982. Immunol. Rev. 69:5. (IP)
  2. George A, et al. 1994. J. Immunol. 152:1014. (Activ)
  3. Asensi V, et al. 1989. Immunology 68:204. (Activ)
  4. Domiati-Saad R, et al. 1993. J. Immunol. 151:5936. (Activ)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Monteith CE, et al. 1996. Can. J. Vet. Res. 60:193. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Chang C L-T, et al. 2007. J. Immunol. 178:6984.
  9. Fazilleau N, et al. 2007. Nature Immunol. 8:753.
  10. Lang GL, et al. 2008. Blood 111:2158. PubMed
  11. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  12. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  13. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  14. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  15. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Mugarza E, et al. 2022. Sci Adv. 8:eabm8780. PubMed
  2. Schaefer-Babajew D, et al. 2023. Nature. 613:735. PubMed
  3. Hägglöf T, et al. 2023. Cell. 186:147. PubMed
  4. Yeh CH, et al. 2022. Immunity. 55:272. PubMed
  5. Dickerson KM, et al. 2022. Blood Cancer Discov. 3:240. PubMed
  6. Lin J, et al. 2022. Adv Sci (Weinh). 9:e2202633. PubMed
  7. Yu‐Han Chang et al. 2017. Immunity. 47(5):943-958 . PubMed
  8. McNamara HA, et al. 2020. Cell Host Microbe. 572:28. PubMed
  9. Kim EH, et al. 2020. Elife. 9:00. PubMed
  10. Wang KC, et al. 2018. Immunohorizons. 2:407. PubMed
  11. Chen S, et al. 2022. Cancer Discov. :. PubMed
  12. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  13. Sangesland M, et al. 2020. Immunity. 51(4):735-749. PubMed
  14. Chen J, et al. 2022. Nat Commun. 13:6759. PubMed
  15. Wang H, et al. 2022. Curr Protoc. 2:e446. PubMed
  16. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
  17. Best SA, et al. 2018. Cell Metab. 27:935. PubMed
  18. Kim SP, et al. 2021. Cell Reports. 36(9):109626. PubMed
  19. Rios D, et al. 2015. Mucosal Immunol. 101038/mi. PubMed
  20. Lopez DA, et al. 2022. Cell Rep. 41:111677. PubMed
  21. Stump CT, et al. 2021. Open Biol. 11:210245. PubMed
  22. Viant C, et al. 2021. J Exp Med. 218:. PubMed
  23. Poon E, et al. 2017. J Immunother Cancer. 10.1186/s40425-017-0268-8. PubMed
  24. Jacque E, et al. 2015. J Exp Med. 212:883. PubMed
  25. Soni C, et al. 2020. Immunity. 52(6):1022-1038.e7. PubMed
  26. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  27. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  28. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  29. Biram A, et al. 2020. Bio Protoc. e3562:10. PubMed
  30. Chatterjee D, et al. 2021. Cell Reports. 35(2):108996. PubMed
  31. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  32. Andersen L, et al. 2020. Cell Reports. 29(13):4447-4459.e6.. PubMed
  33. Zhou X, et al. 2021. Cell Reports. 34(1):108601. PubMed
  34. Cunha LD et al. 2018. Cell. 175(2):429-441 . PubMed
  35. Clancy–Thompson E, et al. 2019. EMBO J. 38:e101260. PubMed
  36. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  37. Xu JL, et al. 2022. Front Pharmacol. 13:911663. PubMed
  38. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  39. Coley WD et al. 2018. F1000Research. 2018 Mar 14 [revised 2018 Jan 1] 0.5125. PubMed
  40. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  41. Viant C, et al. 2020. Cell. 183:1298. PubMed
  42. Schuh E, et al. 2017. J Immunol. 198:3081. PubMed
  43. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  44. Viant C, et al. 2021. STAR Protocols. 2(2):100389. PubMed
  45. Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
  46. Finkin S et al. 2019. Immunity. 51(2):324-336 . PubMed
RRID
AB_11203907 (BioLegend Cat. No. 103243)
AB_11203907 (BioLegend Cat. No. 103244)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

B cells, T cell subset, NK cell subset

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Cell Type
B cells, NK cells, T cells
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID 5788 View all products for this Gene ID
UniProt
View information about CD45R on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD45R/B220 Reagents Request Custom Conjugation
Description Clone Applications
Alexa Fluor® 594 anti-mouse/human CD45R/B220 RA3-6B2 IHC-F,FC,3D IHC
APC anti-mouse/human CD45R/B220 RA3-6B2 FC
Biotin anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F
FITC anti-mouse/human CD45R/B220 RA3-6B2 FC
PE anti-mouse/human CD45R/B220 RA3-6B2 FC
PE/Cyanine5 anti-mouse/human CD45R/B220 RA3-6B2 FC
Purified anti-mouse/human CD45R/B220 RA3-6B2 FC,CyTOF®,IHC-F,IHC-P,IP,Activ
PE/Cyanine7 anti-mouse/human CD45R/B220 RA3-6B2 FC
APC/Cyanine7 anti-mouse/human CD45R/B220 RA3-6B2 FC
Alexa Fluor® 488 anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F,3D IHC
Alexa Fluor® 647 anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Alexa Fluor® 700 anti-mouse/human CD45R/B220 RA3-6B2 FC
PerCP anti-mouse/human CD45R/B220 RA3-6B2 FC
PerCP/Cyanine5.5 anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 421™ anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F
Brilliant Violet 570™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 650™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 605™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 785™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 510™ anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F,SB
Purified anti-mouse/human CD45R/B220 (Maxpar® Ready) RA3-6B2 FC,CyTOF®
Brilliant Violet 711™ anti-mouse/human CD45R/B220 RA3-6B2 FC
PE/Dazzle™ 594 anti-mouse/human CD45R/B220 RA3-6B2 FC
APC/Fire™ 750 anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 750™ anti-mouse/human CD45R/B220 RA3-6B2 FC
TotalSeq™-A0103 anti-mouse/human CD45R/B220 RA3-6B2 PG
Spark Blue™ 550 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark NIR™ 685 anti-mouse/human CD45R/B220 RA3-6B2 FC
TotalSeq™-B0103 anti-mouse/human CD45R/B220 RA3-6B2 PG
Ultra-LEAF™ Purified anti-mouse/human CD45R/B220 RA3-6B2 FC,CyTOF®,IHC-F,IHC-P,IP,Activ
TotalSeq™-C0103 anti-mouse/human CD45R/B220 RA3-6B2 PG
PE/Fire™ 640 anti-mouse/human CD45R/B220 RA3-6B2 FC
APC/Fire™ 810 anti-mouse/human CD45R/B220 RA3-6B2 FC
PE/Fire™ 700 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark Violet™ 538 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark YG™ 581 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark YG™ 570 anti-mouse/human CD45R/B220 RA3-6B2 IHC-F
PE/Fire™ 810 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark Blue™ 574 anti-mouse/human CD45R/B220 Antibody RA3-6B2 FC
Spark Violet™ 423 anti-mouse/human CD45R/B220 Antibody RA3-6B2 FC
Spark Red™ 718 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark UV™ 387 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark PLUS UV395™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Go To Top Version: 2    Revision Date: 04/25/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account